EDAP TMS S.A. Completes FDA Q&A Session For Its Ablatherm-HIFU Pre-Market Approval Application
Published: Mar 20, 2014
LYON, France, March 20, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that it has completed its response to questions from the FDA regarding the Company's Ablatherm-HIFU Pre-Market Approval ("PMA") application, closing this step within the U.S. Food and Drug Administration ("FDA") review process.
Help employers find you! Check out all the jobs and post your resume.